| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Dogecoin (CRYPTO: DOGE) highlighted on Thursday its evolution from a “joke” to a serious cryptocurrency now featured in U.S. index cryptocurrency funds.
Dogecoin's official X handle took users on a nostalgic trip, recalling the days when the memecoin was seen as just a "joke," while other cryptocurrencies were “clamoring” to get listed on exchanges and attract major investors.
“Now listen and you'll hear things like ‘…Including the top 10 worldwide cryptos, such as Dogecoin…'”, the account said.
The remark was in reference to 21Shares launching its first exchange-traded funds tracking the price of a basket of cryptocurrencies, including Dogecoin, for U.S. investors.
The FTSE Crypto 10 Index ETF (TTOP) tracks the FTSE Crypto 10 Select Index, a market-cap-weighted index of the top ten largest cryptocurrencies. The 21Shares FTSE Crypto 10 ex-BTC Index ETF (TXBC) tracks a diversified basket of assets, excluding Bitcoin (CRYPTO: BTC).
“Dogecoin still got it,” the memecoin’s official handle said. “Dogecoin isn’t slowing down on its way to becoming the people’s currency.”
See Also: Dogecoin (DOGE) Price Prediction 2025, 2026, 2030
Notably, the REX-Osprey Doge ETF (BATS:DOJE), which holds a combination of DOGE and DOGE derivatives, also provides exposure to the dog-themed cryptocurrency.
Additionally, Grayscale has filed to convert its existing Dogecoin Trust into a spot ETF, while Bitwise is also vying to get its spot ETF listed on Wall Street.
Price Action: At the time of writing, DOGE was exchanging hands at $0.1645, down 4.33% in the last 24 hours, according to data from Benzinga Pro. The coin has shed 19% of its value over the last month.
Read Next:
Photo Courtesy: Stanslavs on Shutterstock.com
Disclaimer: This content was partially produced with the help of Benzinga Neuro and was reviewed and published by Benzinga editors.
